282 related articles for article (PubMed ID: 16759707)
1. An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients.
Masuda S; Inui K
Pharmacol Ther; 2006 Oct; 112(1):184-98. PubMed ID: 16759707
[TBL] [Abstract][Full Text] [Related]
2. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K
Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
[TBL] [Abstract][Full Text] [Related]
3. [Individualized dosage regimen of immunosuppressive drugs based on pharmacokinetic and pharmacodynamic analysis].
Fukudo M
Yakugaku Zasshi; 2007 Jul; 127(7):1081-9. PubMed ID: 17603267
[TBL] [Abstract][Full Text] [Related]
4. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
Staatz CE; Goodman LK; Tett SE
Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
[TBL] [Abstract][Full Text] [Related]
5. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
Staatz CE; Goodman LK; Tett SE
Clin Pharmacokinet; 2010 Mar; 49(3):141-75. PubMed ID: 20170205
[TBL] [Abstract][Full Text] [Related]
6. Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients.
Loh PT; Lou HX; Zhao Y; Chin YM; Vathsala A
Transplant Proc; 2008 Jun; 40(5):1690-5. PubMed ID: 18589174
[TBL] [Abstract][Full Text] [Related]
7. Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors.
Utecht KN; Hiles JJ; Kolesar J
Am J Health Syst Pharm; 2006 Dec; 63(23):2340-8. PubMed ID: 17106006
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics of tacrolimus and sirolimus in renal transplant patients: from retrospective analyses to prospective studies.
Anglicheau D; Legendre C; Thervet E
Transplant Proc; 2007 Sep; 39(7):2142-4. PubMed ID: 17889118
[TBL] [Abstract][Full Text] [Related]
9. Pharmacology of calcineurin antagonists.
Kapturczak MH; Meier-Kriesche HU; Kaplan B
Transplant Proc; 2004 Mar; 36(2 Suppl):25S-32S. PubMed ID: 15041303
[TBL] [Abstract][Full Text] [Related]
10. [Therapeutic monitoring of immunosuppressive drugs: interest of calcineurin activity assessment in liver transplantation].
Blanchet B
Ann Pharm Fr; 2008 Mar; 66(2):96-101. PubMed ID: 18570908
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetic study of ABCB1 and CYP3A5 genes during the first year following heart transplantation regarding tacrolimus or cyclosporine levels.
Jordán de Luna C; Herrero Cervera MJ; Sánchez Lázaro I; Almenar Bonet L; Poveda Andrés JL; Aliño Pellicer SF
Transplant Proc; 2011; 43(6):2241-3. PubMed ID: 21839244
[TBL] [Abstract][Full Text] [Related]
12. Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients.
Masuda S; Goto M; Fukatsu S; Uesugi M; Ogura Y; Oike F; Kiuchi T; Takada Y; Tanaka K; Inui K
Clin Pharmacol Ther; 2006 Jan; 79(1):90-102. PubMed ID: 16413244
[TBL] [Abstract][Full Text] [Related]
13. Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients.
Barrera-Pulido L; Aguilera-García I; Docobo-Pérez F; Alamo-Martínez JM; Pareja-Ciuró F; Nuñez-Roldán A; Gómez-Bravo MA; Bernardos-Rodríguez A
Transplant Proc; 2008 Nov; 40(9):2949-51. PubMed ID: 19010156
[TBL] [Abstract][Full Text] [Related]
14. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.
Tada H; Tsuchiya N; Satoh S; Kagaya H; Li Z; Sato K; Miura M; Suzuki T; Kato T; Habuchi T
Transplant Proc; 2005 May; 37(4):1730-2. PubMed ID: 15919447
[TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphisms in CYP3A5 and MDR1 genes and their correlations with plasma levels of tacrolimus and cyclosporine in renal transplant recipients.
Mendes J; Martinho A; Simoes O; Mota A; Breitenfeld L; Pais L
Transplant Proc; 2009 Apr; 41(3):840-2. PubMed ID: 19376366
[TBL] [Abstract][Full Text] [Related]
16. CYP3A polymorphisms and immunosuppressive drugs in solid-organ transplantation.
Wang J
Expert Rev Mol Diagn; 2009 May; 9(4):383-90. PubMed ID: 19435458
[TBL] [Abstract][Full Text] [Related]
17. Elevated blood concentrations of calcineurin inhibitors during diarrheal episode in pediatric liver transplant recipients: involvement of the suppression of intestinal cytochrome P450 3A and P-glycoprotein.
Maezono S; Sugimoto K; Sakamoto K; Ohmori M; Hishikawa S; Mizuta K; Kawarasaki H; Watanabe Y; Fujimura A
Pediatr Transplant; 2005 Jun; 9(3):315-23. PubMed ID: 15910387
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic analysis of tacrolimus and cyclosporine in living-donor liver transplant patients.
Fukudo M; Yano I; Masuda S; Fukatsu S; Katsura T; Ogura Y; Oike F; Takada Y; Tanaka K; Inui K
Clin Pharmacol Ther; 2005 Aug; 78(2):168-81. PubMed ID: 16084851
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome P450 genetic polymorphisms influence the serum concentration of calcineurin inhibitors in allogeneic hematopoietic SCT recipients.
Onizuka M; Kunii N; Toyosaki M; Machida S; Ohgiya D; Ogawa Y; Kawada H; Inoko H; Ando K
Bone Marrow Transplant; 2011 Aug; 46(8):1113-7. PubMed ID: 21102498
[TBL] [Abstract][Full Text] [Related]
20. Association between cyclosporine concentration and genetic polymorphisms of CYP3A5 and MDR1 during the early stage after renal transplantation.
Azarpira N; Aghdaie MH; Behzad-Behbahanie A; Geramizadeh B; Behzadi S; Malekhoseinie SA; Raisjalal GH; Rahsaz M; Pourgholami A; Sagheb F
Exp Clin Transplant; 2006 Jun; 4(1):416-9. PubMed ID: 16827636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]